Date：26 July (Wednesday)
Time：12:20 – 13:50 (GMT+8)
National Taiwan University Cancer Center
James Chih-Hsin Yang, MD, PhD, received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU, in 2000. He fi¬rst completed his internal medicine residency at the NTU Hospital, and between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He is currently the director and distinguished professor of the Graduate Institute of Oncology at National Taiwan University. He has been a staff member in the Department of Oncology at the University Hospital since 1995 and chair the Department of Oncology between 2015-2020. He was appointed as the superintendent of the National Taiwan University Cancer Center hospital in Aug 2020.
Dr Yang’s research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Dr Yang is a leader in lung cancer clinical studies, especially in the new drug development for lung cancer treatment. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the principal investigator of several studies that led to the global approval of the 2nd-generation irreversible EGFR TKI, afatinib, and the 3rd-generation EGFR TKI, afatinib. He has published more than 300 papers in peer-reviewed scientific journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology, and has served on the editorial board of Annals of Oncology and Lung Cancer. He is the current associate editor of Journal of Thoracic Oncology, Journal of Thoracic Oncology Clinical Research and Report and Nature Scienti¬fic Report. He received the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the distinguished research award of the Taiwan National Science Council 2012-2015, the TECO award for biotechnology in 2015, distinguished research award of the Ministry of Science and Technology, Taiwan, from 2016-2018 and Academic Award from Taiwan Ministry of Education in 2018; Outstanding Scholar Award, Foundation For the Advancement of Outstanding Scholarship 2019 Aug -2021 Jan. Chair Professor Award, Taiwan Ministry of Education, 2021 Feb to 2024 Jan. He is also the highly cited researcher of 2019 and 2020 in Clinical Medicine category awarded by Clarivate Analytics (Web of Science Group). He currently serves on the board of directors of the International Association for the Study of Lung Cancer (IASLC), with an appointment from 2017-2021.